Shares of Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) ended Tuesday session at $12.88 with 2.65 million shares getting traded. Post opening the session at $12.88, the shares hit an intraday low of $12.70 and an intraday high of $12.92 and the price vacillated in this range throughout the day. The company has a market cap of $2.40 billion and the numbers of outstanding shares have been calculated to be 186.56 million shares.
On September 2, 2016 King`s College Hospital NHS Foundation Trust has launched the Allscripts (MDRX) Sunrise solution as the foundation for its new health information system. The organisation selected the Allscripts Sunrise platform in late 2015 and completed the deployment of the solution in only eight months – an unprecedented accomplishment for such an implementation.
King`s College Hospital (KCH) is one of the United Kingdom`s largest teaching hospitals, training more than 900 dentists, 750 doctors and 300 nurses each year. KCH is also one of the UK`s leading tertiary centers, delivering first-class training and education opportunities for the region`s health professionals, as well as providing a solid foundation for the UK`s medical research sector.
“This was fantastic work, managed very capably, and resulting in a seamless launch,” said Professor Julia Wendon, Medical Director at King`s College Hospital. “I`d like to express my thanks to the King`s and Allscripts` teams for their hard work and focus on driving the successful roll out of Allscripts Sunrise. The new system will provide us with an even greater opportunity to transform the care we deliver through the use of better technology for the benefit of patients and users.”
Used by many of the leading hospitals and health systems in the world, Allscripts Sunrise is a suite of clinical solutions designed to be highly-configurable for clinician-specific workflows. Ultimately driving the adoption of clinical-decision support, both patients and providers benefit from the opportunity for improved outcomes.
“The partnership between King`s College Hospital and Allscripts will enable KCH to continue to develop integrated models of care for its patient population,” said Steven Brain, Allscripts UK Managing Director. “The highly successful Allscripts Sunrise implementation is just the beginning – KCH is now equipped to continue significantly advancing health care in the United Kingdom.”
Shares of Qorvo Inc (NASDAQ:QRVO) ended Tuesday session in red amid volatile trading. The shares closed down -1.58 points or -2.74% at $56.02 with 2.52 million shares getting traded. Post opening the session at $57.85, the shares hit an intraday low of $55.45 and an intraday high of $57.85 and the price vacillated in this range throughout the day. The company has a market cap of $7.15 billion and the numbers of outstanding shares have been calculated to be 127.90 million shares.
Qorvo Inc (QRVO) on Aug. 02, 2016 announced financial results for the Company’s fiscal 2017 first quarter, ended July 2, 2016. On a GAAP basis, June quarterly revenue increased 4% year-over-year and 15% sequentially to $698.5 million. Gross margin was 39.6%, operating expenses were $270.7 million, operating income was $5.7 million, and net loss was $5.7 million, or a loss of $0.04 per share based on 127.5 million weighted average shares outstanding. Gross margin decreased sequentially on both a GAAP and non-GAAP basis, primarily due to a mix shift to lower margin products. Operating expenses increased sequentially on both a GAAP and non-GAAP basis, primarily due to higher R&D expenses, increased variable compensation expense, and the addition of GreenPeak Technologies. The higher R&D expense reflects increased investment in high-performance filter designers, SAW and BAW process engineers, and associated material costs for prototypes.
On a non-GAAP basis, gross margin was 48.2%, operating expenses were $168.6 million, operating income was $167.6 million, or 24.0% of sales, and net income was $143.1 million, or $1.08 per diluted share based on 132.6 million weighted average shares outstanding.
Bob Bruggeworth, president and chief executive officer of Qorvo, said, “Qorvo is the number-one or number-two player in the majority of our growth markets, and we are investing to extend our leadership. We are building a technology moat to maintain leadership where we are number one, and where we are number two, we are investing to advance from a challenger to the leader.
“In the June quarter, Qorvo saw customer order activity accelerate as the quarter progressed, and the entire Qorvo Team ran hard to satisfy demand. In the September quarter, we continue to see strong demand in support of this year’s most popular devices, and we’re rapidly expanding our capabilities to develop new highly integrated solutions for large customer opportunities launching in 2017 and 2018.”